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Randomised trials for 
the Fitbit generation
Data from activity trackers and mobile phones can be used to craft personalised 
health interventions. But measuring the efficacy of these “treatments” 
requires a rethink of the traditional randomised trial. 
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mobile health
Are you one of the millions of people who 
count how many steps they take each day, how 
much time they spend exerting themselves, 
or how often they fidget while asleep? If you 
are, then congratulations: you might not have 
known it, but you are part of a movement – 
the quantified-self movement – and all that 
data you are generating is rich with potential 
to improve human health and well-being.
The rise of wearable activity sensors, 
such as Fitbit, Fuelband and Jawbone, has 
generated a lot of public excitement as well 
as interest from the scientific community. 
Behavioural scientists in particular are 
enthused about the opportunities these 
devices provide not only to monitor activity, 
but also to structure behavioural interventions 
to alter patterns of activity and to help people 
lead healthier lives.
Consider the example of HeartSteps, a 
mobile health application that seeks to reduce 
sedentary behaviour. The app is installed 
on a smartphone which, when paired with a 
Jawbone device, monitors data such as steps 
taken per minute, a user’s current activity and 
location, weather conditions, time of day and 
day of the week. HeartSteps then uses this 
data to come up with suggestions for physical 
activity which are adapted to the user’s 
current situation. 
Like many mobile health interventions, 
HeartSteps attempts to support behaviour 
change by providing users with choices 
that could have a positive impact on health, 
such as deciding to go for a walk during the 
lunch hour, or standing up while conducting 
conference calls. But as with many other types 
of treatment, it is unclear if the treatments 
proposed by HeartSteps actually produce the 
intended response. 
Furthermore, there may be differences in 
treatment effects, both between individuals 
and within the same individual over time. If 
this “heterogeneity” exists, then, to maximise 
the impact of mobile health interventions, it 
may be desirable to adapt interventions so that 
they are only suggested at times and within 
contexts where they are likely to have the 
hoped-for effect.
In some cases we can identify these 
contexts using current theory, clinical 
expertise and initial consultations with users. 
In less clear-cut cases, evidence, in the form 
of data, should be brought to bear. But the 
traditional randomised trial designs that 
produce data for other areas of health and 
medicine – whether for assessing treatment 
effects or adapting interventions – are 
not well suited to mobile health. Perhaps 
the “micro-randomised trial” can fill this 
knowledge gap?
A new trial design
Micro-randomised trials are trials in which 
participants are randomly assigned a 
treatment from the set of possible treatment 
actions at several times throughout the day.  
Thus each participant may be randomised 
hundreds or thousands of times over the 
course of a study. This is very different than 
a traditional randomised trial, in which 
participants are randomised once to one of a 
handful of treatment groups.
In the HeartSteps example, we want 
to know whether providing an activity 
suggestion increases the near-term physical 
activity of a user compared to those who 
do not receive an activity suggestion. We 
are also interested in learning whether the 
activity suggestions are more effective when 
the weather is good compared to when 
the weather is poor, or whether the effect 
of the activity suggestion is influenced by 
the busyness of the user’s calendar.  The 
micro-randomised trial can provide data for 
investigating these and other questions.
HeartSteps is a 42-day trial leading to 
210 decision points per participant (or five 
decisions per participant per day). At each 
decision point a set of treatment actions 
is possible. These can include the type of 
treatment to provide, as well as whether to 
provide treatment at all. In general the set of 
potential treatment actions may depend on the 
state of the individual as well as the previously 
assigned treatments.  For example, the set 
of treatments at once-a-day decision times 
may contain two alternative daily-step goal 
treatments – one a fixed 10 000-steps-a-day 
goal, the other an adaptive goal depending on 
previous activity levels.  Treatments may be 
delivered via the smartphone, as in Figure 1, or 
via other wearable devices such as a wristband. 
The treatment actions are often designed 
to have near-term effects on a longitudinal 
response, which we call the “proximal 
response”. In the HeartSteps study, the 
proximal response is a participant’s step count 
in the hour following the intervention.
Interventions are randomised, but 
the randomisation probabilities may not 
be uniform across the set of treatment 
actions. Furthermore, the randomisation 
can vary within a person. For example, the 
randomisation probabilities may differ by 
how busy the individual’s calendar is over the 
next hour.
In the HeartSteps example, the 
probability of providing an activity suggestion 
is set to 40% so that individuals are provided 
an average of two interventions per day. 
That level was decided based on a range of 
considerations, including the risk of treatment 
burden leading to dropout, the intrusiveness 
of interventions and concerns that users 
would begin to ignore activity suggestions 
through habituation. 
Finally, as is the case for most clinical 
trials, the sample size for a micro-randomised 
trial is determined to guarantee a specified 
power to test one or at most a few very specific 
hypotheses.1 However, the resulting data can 
be used to investigate a variety of questions 
useful in designing a mobile intervention. 
Statistical challenges 
In this era of personalised medicine and 
complex mobile health interventions, the 
Figure 1. Example activity message from HeartSteps
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micro-randomised trial provides a new 
experimental paradigm. But even though this 
trial design is very new, there is already at least 
one completed trial,2 while we (the authors) 
are involved in both the HeartSteps trial as 
well as a trial on smoking cessation that was 
scheduled to begin in late autumn 2015. There 
are also numerous trials in the proposal stages. 
It is a positive start, though more work is 
necessary in the area of experimental design 
for mobile health. Interesting challenges 
include how best to design a clinical trial that 
ensures a given power to detect interactions 
between different intervention factors. Many 
questions involving causal inference arise 
in mobile health, and so causal inference 
methods must be extended to mobile health 
and micro-randomised trials in particular. 
Some immediate needs are data analysis 
methods that can model and assess the 
existence of delayed effects of interventions. 
For example, an activity suggestion may not 
induce the participant to be physically active 
in the next hour, but it may inspire that 
person to be more active over the course of 
the next day.
Second, in many mobile health settings, 
the proximal response is not the primary 
clinical outcome. A mobile health intervention 
to tackle smoking might, for example, include 
treatments that are designed to help a person 
manage momentary stress or momentary 
urges to smoke. So here the proximal response 
is stress or urge to smoke, yet the clinical 
outcome is time to relapse to smoking. 
Natural methods from causal inference 
concern the use of surrogate outcomes or 
mediation analyses. These causal inference 
methods need to be generalised to the mobile 
health setting, as do methods from the field of 
missing data, because missing data is rampant 
in mobile health trials due to slippage of 
wearable devices, problems with wireless 
connectivity and user non-adherence.
In addition, there are a multitude of 
secondary analyses that are possible using 
data arising from a micro-randomised trial. 
Beyond delayed effects, the examination of 
effect moderation – testing for the treatment 
effect conditional on covariate history – is 
of interest. Mobile health data can also 
be used to predict latent states, such as 
underlying stress levels given associated sensor 
measurements. Latent state models may be 
useful in the prediction of time-to-event 
outcomes, such as time until next cigarette 
and drug lapse or relapse more generally. 
Finally, the data is useful for building 
optimal mobile health treatment policies 
for future patients, by estimating the best 
treatment action to take given a patient’s 
observed history. In HeartSteps, for example, 
the data can help determine the timing of 
activity suggestions to maximise the patient’s 
long-term physical activity.
Individual experience
Secondary analyses are also of interest 
because of concerns that there are systematic 
differences, both between individuals and 
within individuals, in response to treatment 
actions in the mobile health setting. This is 
the type of concern that motivates research 
in personalised and precision medicine. It is 
unclear if the response variability between 
individuals and within individuals can be 
captured by covariate information, but given 
the sequential interlacing of time-varying 
covariates with randomised treatment actions, 
we believe that the micro-randomised trial 
provides a unique opportunity to investigate 
treatment effect differences. This point 
deserves significant emphasis as science begins 
to tackle problems in maximising not only 
population health, but also the health of each 
particular individual.
A further interesting challenge in 
mobile health is whether and how any 
mobile intervention can be optimised in real 
time – that is, as the individual experiences 
the treatments and responses are recorded. 
Multi-armed bandit and contextual bandit 
learning algorithms provide a promising 
approach to optimisation. These learning 
algorithms use sequential randomisations 
that are increasingly biased towards the 
treatment that appears, according to 
past data, most effective. They have been 
popularised in the online advertising space by 
Google and Facebook. 
A critical assumption underlying bandit 
algorithms is that the current treatment (or 
ad placement) will not impact the type/
context of the subsequent participant. This 
assumption is likely to be valid in many 
advertising applications as the randomisation 
of ‘treatments’ is sequential and between 
participants as they visit the website, as 
opposed to within a participant. Similarly in 
mobile health, if the influence that a treatment 
has on participant learning, treatment fatigue 
and non-adherence is low, then the above 
assumption may be approximately correct. 
Rabbi et al., as well as members of our team, 
are currently investigating the extent to which 
bandit algorithms might be used to optimise 
mobile interventions in real time.3,4
Alternatives to micro-randomisation
An alternative to the micro-randomised trial design is the single-case design used in the 
behavioural sciences. These trials usually only involve a small number of participants 
(fewer than 10) and the data analyses focus on the examination of visual trends for each 
participant separately. 
In these trials, each participant is subject to periods of treatment interspersed with periods 
of no treatment. For example, during periods when a participant is on treatment, one might 
expect the response to be generally higher than the response during the time periods in which 
the participant is off treatment. 
An excellent overview of single-case designs and their use for evaluating technology-based 
interventions is Dallery et al.6 This paper illustrates the visual analyses that would be conducted 
on each participant’s data. A critical assumption is that the effect of the treatment is only 
temporary (no carry-over effect) so that each participant can act as his own control. 
Additionally, one generally assumes that the effect of a treatment is constant over time. In 
settings in which treatments are expected to have sufficiently strong effects so as to overwhelm 
the within-person variability in response, these designs provide a nice alternative to the micro-
randomised trial design.
Kratochwill and Levin consider a variety of ways to introduce randomisation into the 
single-case design, including randomising the order of treatment/baseline phases.7 The micro-
randomised trial design can be viewed as a statistical generalisation of the single-case design, 
both in terms of involving multiple participants and including more traditional statistical 
analyses with sample size formula for the number of participants.
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The dawn of data-based 
mobile health
Mobile devices and wearable activity sensors 
hold the promise of providing low-cost 
supportive behavioural interventions and 
thus lowering medical costs, particularly for 
those individuals struggling with chronic 
conditions. It is no wonder that behavioural 
scientists are excited by the potential and have 
begun to incorporate these new methods in 
their work.
However, as Stephen Senn warned in 
2001 with respect to the advance of genomic 
data in the health fields, the potential of 
new technologies may not be realised.5 We, 
however, have high hopes for this technology, 
though we caution against the slow pace of 
development of corresponding statistical 
methods for the rigorous collection and study 
of data in mobile health. 
The micro-randomised trial described 
here is just a first step towards designing 
experiments in mobile health. These 
methods should provide a rigorous statistical 
framework and will hopefully lead to effective 
mobile health interventions.
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